Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

Dong-Wan Kim,Shirish Gadgeel,Scott N Gettinger,Gregory J Riely,Geoffrey R Oxnard,Tarek Mekhail,Peter Schmid,Afshin Dowlati,Rebecca S Heist,Antoinette J Wozniak,Jatinder Singh,Edward Cha,Jessica Spahn,Sai-Hong Ignatius Ou

JTO Clinical and Research Reports（2022）

引用 10|浏览15

暂无评分

摘要

The combination of alectinib and atezolizumab is feasible, but increased toxicity was found compared with the individual agents. With small sample sizes and relatively short follow-up, definitive conclusions regarding antitumor activity cannot be made.

查看译文

关键词

Alectinib,Atezolizumab,ALK-positive,Non–small cell lung cancer,Phase 1b study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要